ABSTRACT
This paper proposes a novel method to estimate rainfall intensity by analyzing the sound of raindrops. An innovative device for collecting acoustic data was designed, capable of blocking ambient noise in rainy environments. The device was deployed in real rainfall conditions during both the monsoon season and non-monsoon season to record raindrop sounds. The collected raindrop sounds were divided into 1 s, 10 s, and 1 min intervals, and the performance of rainfall intensity estimation for each segment length was compared. First, the rainfall occurrence was determined based on four extracted frequency domain features (average of dB, frequency-weighted average of dB, standard deviation of dB, and highest frequency), followed by a quantitative estimation of the rainfall intensity for the periods in which rainfall occurred. The results indicated that the best estimation performance was achieved when using 10 s segments, corresponding to the following metrics: accuracy: 0.909, false alarm ratio: 0.099, critical success index: 0.753, precision: 0.901, recall: 0.821, and F1 score: 0.859 for rainfall occurrence classification; and root mean square error: 1.675 mm/h, R2: 0.798, and mean absolute error: 0.493 mm/h for quantitative rainfall intensity estimation. The proposed small and lightweight device is convenient to install and manage and is remarkably cost-effective compared with traditional rainfall observation equipment. Additionally, this compact rainfall acoustic collection device can facilitate the collection of detailed rainfall information over vast areas.
ABSTRACT
Increasing evidence suggests an association between SARS-CoV-2 vaccines and Guillain-Barré syndrome (GBS). Nevertheless, little is understood about the contributing risk factors and clinical characteristics of GBS post SARS-CoV-2 vaccination. In this prospective surveillance study of 38,828,691 SARS-CoV-2 vaccine doses administered from February 2021 to March 2022 in the Gyeonggi Province, South Korea, 55 cases of GBS were reported post vaccination. We estimated the incidence rate of GBS per million doses and the incidence rate ratio for the vaccine dose, mechanism, age, and sex. Additionally, we compared the clinical characteristics of GBS following mRNA-based and viral vector-based vaccinations. The overall incidence of GBS following SARS-CoV-2 vaccination was 1.42 per million doses. Viral vector-based vaccines were associated with a higher risk of GBS. Men were more likely to develop GBS than women. The third dose of vaccine was associated with a lower risk of developing GBS. Classic sensorimotor and pure motor subtypes were the predominant clinical subtypes, and demyelinating type was the predominant electrodiagnostic subtype. The initial dose of viral-vector based vaccine and later doses of mRNA-based vaccine were associated with GBS, respectively. GBS following SARS-CoV-2 vaccination may not be clinically distinct. However, physicians should pay close attention to the classic presentation of GBS in men receiving an initial dose of viral vector-based SARS-CoV-2 vaccines.
